MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study

Auteurs

Emeline Tabouret, François Bertucci, Jean-Yves Pierga, Thierry Petit, Christelle Levy, Jean-Marc Ferrero, Mario Campone, Joseph Gligorov, Florence Lerebours, Henri Roché, Thomas Bachelot, Steven van Laere, Naoto T. Ueno, Yves Toiron, Pascal Finetti, Daniel Birnbaum, Jean-Paul Borg, Patrice Viens, Olivier Chinot, Anthony Gonçalves